APIM Therapeutics Nets New Round

APIM Therapeutics, a preclinical biotech company targeting cancer therapeutics, has closed a new round to continue drug development. Investors included Norsk Innovasjonskapital III AS, Birk Venture and Sarsia Seed.

North AmericaUSBriefs